TICKERNERD
Menu
KURAKURAHealthcare · Biotechnology

KURA Stock Forecast: Kura Oncology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$12
+1.54% on the day

The 15 Wall Street analysts covering Kura Oncology, Inc. hold a median 12-month price target of $28 — +135.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.1B
Ticker Nerd rank
80 / 100
Median analyst target
$28
Analysts covering
15
Total return, dividends reinvested
1W
+9.5%
1M
+9.2%
YTD
+14.4%
1Y
+59.8%
From 52W high
−5.1%
From 52W low
+60.7%
$7
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kura Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Momentum
89
Revisions
83
Value
75
Volatility
70
Quality
57
Size
44
Issuance
34
Growth
21

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (21): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26KURAHigh $76Median $28Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $15Median $28High $76

The green dot is the last close — the median target sits +135.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026WedbushMaintainsOutperform$36 → $38
28 July 2026WedbushReiteratesOutperform$36
28 July 2026WedbushReiteratesOutperform—
15 June 2026CitizensReiteratesMarket Outperform$24
15 June 2026CitizensReiteratesMarket Outperform—
14 Apr 2026Lake StreetInitiatesBuy—
24 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026UBSMaintainsBuy—
6 Mar 2026WedbushMaintainsOutperform—
13 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Jan 2026Leerink PartnersMaintainsOutperform—
24 Nov 2025BarclaysMaintainsOverweight—
14 Nov 2025UBSMaintainsBuy—
14 Nov 2025WedbushMaintainsOutperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025JMP SecuritiesReiteratesMarket Outperform—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
4 Sept 2025GuggenheimInitiatesNeutral—
11 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
26 June 2025Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Kura Oncology, Inc. (KURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.7×

Cheaper than 88% of US stocks

Price / sales
13.7×

Cheaper than 12% of US stocks

Price / book
21.9×

Cheaper than 5% of US stocks

EV / EBITDA
−1.8×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
36.5%

Higher than 82% of US stocks

Earnings growth (YoY)
29.5%

Higher than 66% of US stocks

Gross margin
98.6%

Higher than 99% of US stocks

Operating margin
−349.8%

Higher than 9% of US stocks

Net margin
99.9%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−167.7%

Higher than 8% of US stocks

Return on assets
−31.3%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KURAKura Oncology, Inc.$1.1B
80
JANXJanux Therapeutics, Inc.$1.0B
74
AVTXAvalo Therapeutics, Inc.$1.0B
43
ABUSArbutus Biopharma Corp.$1.0B
97
LXRXLexicon Pharmaceuticals, Inc.$1.0B
68
WVEWave Life Sciences, Inc.$1.0B
16
SVRASavara, Inc.$1.1B
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kura Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KURA news & analysis

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research · 19 Aug 2026neutral

Zacks Investment Research published an article examining whether Kura Oncology (KURA) qualifies as a strong momentum stock pick for investors. The piece poses the question of whether the company has what it takes to be a top momentum pick.

Why it matters — KURA watchers would care because the article evaluates the company's momentum characteristics, which can signal how the stock is currently being viewed by market participants.

Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?

Zacks Investment Research · 18 Aug 2026positive

Zacks reports that the mean of Wall Street analysts' price targets for Kura Oncology points to roughly 178.6% upside in the stock, while noting this metric has not proven highly effective. The report also indicates that strong agreement among analysts in raising earnings estimates suggests potential upside for the company.

Why it matters — A KURA watcher would care because the article highlights analyst expectations of significant upside and rising earnings estimates for the stock.

Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published Kura Oncology's Q2 2026 earnings call transcript, providing investors a full record of management's discussion during the conference call.

Why it matters — KURA watchers would rely on this transcript for direct insight into management's commentary on the company's quarterly performance and outlook.

Kura Oncology Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

Kura Oncology reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, noting the drug captured a majority share of new patient starts in the menin inhibitor market for that indication.

Why it matters — The revenue figure and market-share data provide an early read on KOMZIFTI's commercial traction in its approved indication.

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 12 Aug 2026positive

Kura Oncology reported a second-quarter loss of $0.77 per share, narrower than the Zacks Consensus Estimate of a $0.89 loss but wider than the $0.75 loss reported a year ago.

Why it matters — The smaller-than-expected quarterly loss could signal improved cost management or financial performance relative to analyst projections.

FAQ

Frequently asked questions about KURA stock

What is the KURA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Kura Oncology, Inc. have a median 12-month price target of $28, with estimates ranging from $15 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KURA stock a buy right now?

Of the 15 analysts covering Kura Oncology, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kura Oncology, Inc. 80 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KURA?

As at 22 Aug 2026, Kura Oncology, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will KURA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +135.5% from the last close, and Ticker Nerd's factor model ranks Kura Oncology, Inc. 80 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KURA stock forecast for 2030?

No analyst covering Kura Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $76 over the next 12 months.

How has KURA stock performed over the past year?

Kura Oncology, Inc. returned +59.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kura Oncology, Inc. do?

Kura Oncology Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of precision medicines for cancer treatment.

What is the latest news on KURA?

The most recent item we track (Zacks Investment Research, 19 Aug 2026): "Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?". Zacks Investment Research published an article examining whether Kura Oncology (KURA) qualifies as a strong momentum stock pick for investors. The piece poses the question of whether the company has what it takes to be a top momentum pick.

Company

About Kura Oncology, Inc.

Kura Oncology Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of precision medicines for cancer treatment. It specializes in novel therapies that selectively target cancer cells, addressing areas with significant unmet medical needs such as HRAS mutant solid tumors, chronic myelomonocytic leukemia, MAPK pathway tumors, and acute leukemias. The company's pipeline features Tipifarnib, a farnesyl transferase inhibitor; KO-947, an ERK inhibitor; and KO-539, a Menin-MLL inhibitor, alongside approved products like Komzifti (ziftomenib) for specific leukemias. Kura Oncology Inc. advances precision oncology by developing targeted treatments that aim to improve patient outcomes in oncology. Founded in 2014 and headquartered in San Diego, California, it operates in the biopharmaceutical sector, contributing to innovative cancer care through its clinical-stage programs.

CEO Dr. Troy Edward Wilson J.D., Ph.D. · 260 employees · United States · https://kuraoncology.com